

Biochemical and structural analysis of N-myristoyltransferase mediated protein tagging

Paul Monassa, Frédéric Rivière, Cyril Dian, Frédéric Frottin, Carmela Giglione, Thierry Meinnel

► To cite this version:

Paul Monassa, Frédéric Rivière, Cyril Dian, Frédéric Frottin, Carmela Giglione, et al.. Biochemical and structural analysis of N-myristoyltransferase mediated protein tagging. Methods in Enzymology, 2023, Modifications and Targeting of Protein Termini: Part A, 684, pp.135-166. 10.1016/bs.mie.2023.02.016 . hal-04234963

HAL Id: hal-04234963 https://hal.science/hal-04234963v1

Submitted on 10 Oct 2023 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 CHAPTER FIVE

2

Biochemical and structural analysis of N-myristoyltransferase-mediated protein tagging

- 5
- Paul Monassa^{iD,a,£}, Frédéric Rivière^{iD,a,1,£}, Cyril Dian^{iD,a}, Frédéric Frottin^{iD,a}, Carmela
 Giglione^{iD,@,a}, Thierry Meinnel^{iD,@,a,*}
- 8
- 9 ^a Université Paris Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC),
- 10 91198 Gif-sur-Yvette cedex, France
- 11
- 12 **Running title**: N-myristoylation-related biochemical methods
- 13 Correspondence: <u>carmela.giglione@i2bc.paris-saclay.fr (C. Giglione)</u> or
- 14 thierry.meinnel@i2bc.paris-saclay.fr (T. Meinnel)
- ¹⁵ ^{iD} ORCID iD 0001-6366-1904 (F. Rivière); 0003-4713-8069 (P. Monassa); 0002-6349-3901
- 16 (C. Dian); 0002-2756-7838 (F. Frottin); 0002-7475-1558 (C. Giglione); 0001-5642-8637 (T.
- 17 Meinnel)
- 18 [@]twitter @giglionelab (C. Giglione); @meinnel (T. Meinnel)
- 19 [£] These authors contributed equally
- 20 Present address
- ¹ Karolinska Institutet, Department of Biosciences and Nutrition, 14183 Huddinge, Sweden
 22
- 23 Keywords: Protein acylation; lysine; myristoylation; acetylation; N-myristoyltransferase; N-
- 24 terminus; glycine; protein modification; fatty acid
- 25

26	Contents				
27 28	1. Introduction				
20					
30	2.1 Equipment	5			
31	2.1.1 Instruments				
32	2.1.2 Small items				
33	2.2 Plasmids, strains, and growth medium for protein expression	6			
34	2.2.1 Plasmids	6			
35	2.2.2 Bacterial growth	7			
36	2.3 Enzymes	7			
37	2.3.1 Commercial	7			
38	2.3.2 NMTs				
39	2.3.3 IpaJ protease	10			
40	2.4 Reagents	.11			
41	2.4.1 Fatty acyl derivatives	.11			
42	2.4.2 Peptides				
43	2.4.3 Reactants for gel imaging	12			
44	2.5 Buffer components	13			
45	2.5.1 For storage at room temperature	13			
46	2.5.2 For storage at -20°C	13			
47	3. Preparation of noncommercial N-myristoyl protein or CoA derivatives	13			
48	3.1 Myristoyl-CoA and any unusual CoA acyl derivatives	14			
49	3.2 Myristoylated protein substrates	14			
50	3.2.1 Fatty acid tagging of target proteins with NMT in vitro				
51	3.2.2 Myristoyl tagging in cell free translation systems				
52	3.2.3 Bacteria-driven target labeling				
53	3.2.4 Quality controls				
54	4. Characterization of NMT-induced modifications on protein targets				
55	4.1 General considerations				
56	4.2 MALDI mass spectrometry				
57	4.2.1 Main outlines				
58	4.2.2 Notes	20			
59	4.3 The NMT/IpaJ pipeline				
60	4.4 Click chemistry-based protein imaging	22			
61	4.4.1 Overview	22			

62	4.4.2	In cellulo labeling procedures with acyl precursors	23		
63	4.4.3	In-gel imaging	24		
64	4.4.4	Immunoprecipitation	25		
65	4.4.5	Fluorescence imaging after immunoblotting	25		
66	5. Struct	tural studies of NMT and its complexes with substrates and products	26		
67	5.1 S	tructural overview	26		
68	5.2 C	rystallization and structure determination	27		
69	5.2.1	General crystallization conditions	27		
70	5.2.2	Obtaining crystals of NMT in complex with reactants or reaction in	termediates		
71		27			
72	5.2.3	Dataset collection, structure resolution, and refinement	29		
73	6. Concl	usions and future prospects	30		
74	Acknowledgements				
75	Funding				
76	References				
77	Figure Legends				
78	_				
79					

80 Abstract

81 N-terminal myristoylation is an essential eukaryotic modification crucial for cellular 82 homeostasis in the context of many physiological processes. Myristoylation is a lipid 83 modification resulting in a C14 saturated fatty acid addition. This modification is challenging 84 to capture due to its hydrophilicity, low abundance of target substrates, and the recent discovery 85 of unexpected NMT reactivity including myristoylation of lysine side chains and N-acetylation 86 in addition to classical N-terminal Gly-myristoylation. This chapter details the high-end 87 approaches developed to characterize the different features of N-myristoylation and its targets 88 through in vitro and in vivo labeling.

89

90 1. Introduction

91 N-myristoyltransferases (glycylpeptide N-tetradecanoyltransferases, myristoyl 92 CoA:protein N-myristoyltransferases, NMT; EC 2.3.1.97) are a class of essential enzyme 93 catalysts of protein myristoylation. NMTs target N-terminal glycines (Gly-myristoylation) 94 usually unmasked by co-translational methionine excision (Giglione & Meinnel, 2022; 95 Meinnel, Dian, & Giglione, 2020). A general scheme of classical NMT reactivity is provided 96 in Fig. 1A. The initiator methionine is removed by methionine aminopeptidases (MetAPs, 97 EC:3.4.11.18). Most eukaryotes express two MetAPs, MetAP1 and MetAP2, both of which 98 display high cleavage efficiency of Met-Gly peptide bonds (Frottin et al., 2006; Giglione, 99 Boularot, & Meinnel, 2004). Post-translational proteolytic cleavages induced by caspases 100 (EC:3.4.22.xx) in the context of apoptosis in metazoans may also expose new N-terminal 101 glycines previously embedded within the polypeptide sequence that may similarly undergo 102 Gly-myristoylation (Martin, Beauchamp, & Berthiaume, 2011; Thinon et al., 2014). As caspase 103 3 (EC:3.4.22.56) restricts new N-termini to only small residues (i.e., Ala, Gly, Asn, and Ser),

its cleavage specificity is well suited for this purpose and is the major post-translational
provider of post-translational Gly-myristoylation (Meinnel, 2022; Rivière et al., 2022). Two
percent of multicellular eukaryote proteins are predicted to undergo Gly-myristoylation, mostly
of co-translational origin (Castrec et al., 2018; Meinnel, 2022; Meinnel et al., 2020).

108 However, experimental proof of myristoylation only exists for a minority - most from 109 human - of protein targets. Evidence of myristoylation of a novel target protein is often 110 indirect, for instance by establishing protein localization with or without the N-terminal Gly, 111 which is usually substituted with an Ala (Traverso et al., 2013b). This so-called G2A 112 substitution is known to inhibit myristoylation (Gordon, Duronio, Rudnick, Adams, & Gokel, 113 1991). Robust biochemical approaches for investigating NMT targeting were initially reported 114 in the 1990s (see, for instance, (Rudnick, Duronio, & Gordon, 1992) and this series, volume 115 250, chapters 29-37, (Casey & Buss, 1995)). However, in the early 2010s, new technologies 116 emerged to study myristoylation including state-of-the-art mass spectrometry, click and 117 bioorthogonal chemistry, and new structural approaches. This chapter is dedicated to the main 118 approaches available for deciphering the modification state of NMT targets.

119

- 120 **2.** Materials, reagents, and buffers
- 121 2.1 Equipment
- 122 2.1.1 Instruments

Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometer
 for mass spectrometry (MS) and MS/MS spectra acquisition (AB Sciex LLC; MALDI TOF/TOF 5800 instrument).

Nano liquid chromatography-coupled electrospray mass spectrometer (Dionex UltiMate
 3000; AB Sciex LLC, TripleTOF 4600) for exact mass determination of entire proteins larger
 than 30 kDa.

Multicolor fluorescence imager (Typhoon RGB Biomolecular Imager, GE Healthcare)
 equipped with 532 nm-excited fluorescence and 580 nm bandpass (580 BP 30) filter for
 wavelength emission range of 565–595 nm suited to Cy3 or TAMRA fluorochromes. The 633
 nm-excited fluorescence with 670 nm bandpass (670 BP 30) for wavelength emission detection
 range of 655–685 nm is suited to Cy5-type probe detection. Note that Typhoon Trio imagers
 offer additional chemiluminescence detection.

• Chemiluminescence and staining imaging system equipped with Chemi/UV/Stain-Free tray

136 (ChemDoc Touch, Bio-Rad).

• Ultrasonic sonicator (Q700, Qsonica) equipped with a 12 mm Macrotip (amplitude 120 μm).

138 2.1.2 Small items

Precast gels (12%) for electrophoretic separation in standard Tris-glycine buffer (MiniPROTEAN TGX, Bio-Rad, 4561043).

- Polyvinylidene fluoride (PVDF) immunoblot membranes (Immun-Blot Low Fluorescence
 membranes, Bio-Rad, 1620260-4).
- Bradford assay kit (Bio-Rad, 500001) for protein quantification determined against a
 standard bovine serum albumin (BSA) calibration curve (Bradford, 1976).
- Lipofectamine 3000 (Thermo Fisher Scientific, L3000015) for cell transfection.
- Polyethylene glycol 6000 (Sigma-Aldrich, 81260) for protein crystallization.

147 2.2 Plasmids, strains, and growth medium for protein expression

148 2.2.1 Plasmids

• pET28b tobacco etch virus (TEV) vector (LifeScience Market, PVT10578) featuring a 6-His
 tag. We use a similar but in-lab-engineered version of pET28a TEV featuring a 10-His tag as
 described below. Expression requires kanamycin (50 μg/mL) in the growth medium.

• pET16b (Novagen, 69662). Expression requires 50 μg/mL ampicillin in the growth medium.

• pETM30 is a pET28b derivative featuring an N-terminal-GST fusion (Dümmler, Lawrence,

154 & De Marco, 2005). Expression requires kanamycin (50 μ g/mL) in the growth medium.

• pET21-ARF6-His6, a kind gift from M. Franco (IPMC, Nice, France) for ARF6-His
overexpression and purification in *E. coli*. ARF6-His6 is 21.0 kDa (ARF6 is 19.9 kDa).

• pJAF211 (Addgene, 52407) for ARF6-Flag overexpression in mammalian cells. The cDNA

158 sequence originates from mice and encodes the same peptide chain as in humans. The Flag-tag

- 159 is at the C-terminal. ARF6-Flag is 23.8 kDa.
- pETDuet-1 (Novagen) for dual overexpression of both NMT and target protein of interest
 cDNAs.

162 2.2.2 Bacterial growth

- Rosetta 2-DE3pLys bacterial strain (Novagen). Genotype is F^- ompT gal dcm lon hsdS_B(r_B^-
- 164 m_B^{-}) λ (DE3 [*lacI lacUV5-T7p07 ind1 sam7 nin5*]) [*malB*⁺]_{K-12}(λ ^S)). pLysSRARE produces T7
- 165 lysozyme and tRNA genes to supplement *E. coli* rare codons AGG, AGA, AUA, CUA, CCC,
- 166 and GGA. Add chloramphenicol (34 μ g/mL) to ensure plasmid propagation in the growth 167 medium.
- 2xTY growth medium. Mix 16 g Bacto Tryptone, 10 g Bacto Yeast Extract, and 5 g NaCl in
 900 mL distilled H₂O. Adjust the pH to 7.0 with NaOH and finally adjust to 1 L with distilled
 H₂O. Sterilize by autoclaving.
- 171 **2.3 Enzymes**
- 172 2.3.1 Commercial

173 • Acyl-CoA synthetase (ACS; EC 6.2.1.3) from Pseudomonas sp. (Creative Enzymes, NATE-1712; 15 U/mg; 1000 U). Dilute the sample to 1 U/ μ L in 5 mM Tris-HCl pH 7.4, 1 mM DTT, 174 55% glycerol for storage at -20°C. ACS catalyzes the reaction shown in Fig. 1B. 175 176 • Recombinant TEV (rTEV, EC 3.4. 22.44) protease (Genscript, Z03030, 10 U/µl); rTEV contains the 231 amino acid sequence of TEV fused to an N-terminal His tag. It cleaves the 177 178 Glu-Asn-Leu-Tyr-Phe-Gln/[Gly/Ser] sequence (Kapust et al., 2001) and can be removed by nickel cation affinity assays. To reduce purchase costs, TEV and rTEV can also be 179 180 overexpressed and easily purified from recombinant plasmid vectors (Enríquez-Flores et al.,

182 2.3.2 NMTs

2022; Nautiyal & Kuroda, 2018).

181

In this section, we describe the NMT preparations required for kinetic or structural analysis. Protein concentrations are measured with the aforementioned Bio-Rad kit. Purity needs to be >95% for kinetic analysis and >99.9% for crystallization purposes. We usually clone into a pET16b featuring a Factor Xa protease cleavage or a pET28b derivative vector featuring an N-terminal 10x His tag fused with a TEV protease cleavage site. Expression is performed at 22°C in Rosetta2-DE3pLysS bacterial cells. The protocol reported below relates to HsNMT1[*l*] (Dian et al., 2020) but may be used for any NMT (see below).

190 • Like Factor Xa, the TEV protease-cleavable linker of the inter-domain
191 (CATCACCATCACCATCACCATCACCATCACGAGAATCTTTATTTTCAGGGC;

encoding here Glu-Asn-Leu-Tyr-Phe-Gln/Gly fused in-frame downstream of the His-tag and upstream of the start of the sequence of interest) permits *in vitro* cleavage of the His-tag from the expressed NMT if the pET28-derived vector is used for protein purification. Upon cleavage, the His-tag is removed from the NMT sample of interest by taking advantage of a second affinity column on the same resin. The NMT is easily recovered, as it is not retained 197 and elutes with the flow-through. Unlike TEV or Factor Xa, the rTEV protease is equipped 198 with a His-tag and can also be retained on the second affinity column, allowing its removal and 199 fine purification of an NMT version devoid of protease contaminants, especially useful for 200 crystallization purposes.

• NMTs are easy to overexpress in *Escherichia coli* and purify in two steps, taking advantage
of the N-terminal tags. C-terminal tags need to be avoided, as the C-terminal carboxylate of
NMTs acts as the catalytic base and cannot be engaged in another peptide bond (Dian et al.,
2020). N-terminal deletions of NMT sequences up to the B'A' domain can be achieved without
modification of the catalytic parameters. Trimming of this domain modifies the catalytic
mechanism and tends to increase the turnover number (Dian et al., 2020).

207 • After growth at 37°C in 2 L 2x TY medium supplemented with the *ad hoc* antibiotics until 208 0.4-0.5 OD₆₀₀, the temperature is reduced to 22°C for 30 min to reach 0.7-0.9 OD₆₀₀. Bacteria 209 are induced with 0.4 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) and grown for another 20 h at 22°C under vigorous shaking. Cells are harvested by centrifugation and lysed 210 211 by sonication (amplitude 50%, 10 s on and 30 s off) for 90 s at 4°C after resuspension in 10 212 mL/per g of cell paste in 20 mM Tris-HCl (pH 8.0), 0.5 M NaCl, 5 mM 2-mercaptoethanol, 213 and 5 mM imidazole (buffer C) supplemented with 1 mg/mL lysozyme and 5 µL benzonase. 214 After centrifugation at 40,000 x g, the clarified lysate is loaded at 3 mL/min onto an 215 immobilized nickel ion affinity chromatography column (HisTrap Crude FF, 5 mL, GE 216 Healthcare) and washed with buffer C with 25 mM imidazole. Elution is carried out at 2 217 mL/min with buffer C plus 0.25 M imidazole with a linear gradient.

The pool of purified protein is next dialyzed overnight against 20 mM Tris-HCl (pH 8.9), 150 mM NaCl, 25 mM imidazole, and 5 mM 2-mercaptoethanol in the presence of TEV protease (1 mg per 15 mg purified protein). His-tag-free HsNMT1 is purified with a HisTrap Crude FF column. The flow-through with HsNMT1 is diluted five times in 20 mM Tris-HCl

222 (pH 8.9) and 1 mM DTT (buffer B) and applied to an anion exchange chromatography column

223 (HiTrap Q FF, 5 mL, GE Healthcare). HsNMT1 is eluted with buffer B supplemented with 0.2

224 M NaCl. Finer purification of some NMTs might require a final gel filtration step, but we have

not needed this for our crystallization of HsNMT1.

• Highly purified NMT fractions are pooled, concentrated to 15–30 mg/ mL with an Amicon

227 centrifugal filtration device (Merck Millipore) in 20 mM Tris-HCl (pH 8.0), 0.2 M NaCl, 1

mM DTT, and stored at -80°C before crystallization trials. Protein samples for kinetic analysis
are stored at -20°C in the same buffer plus 55% glycerol.

Human NMT (HsNMT1). The HsNMT1(*l*) isoform containing residues 81-496 corresponds
to the major isoform (Pierre et al., 2007). We cloned HsNMT1(*l*) into pET16b as an N-terminal
His-tag fusion (Pierre et al., 2007), and the recombinant protein was expressed and purified as
described (Castrec et al., 2018). Isoform HsNMT1(*s*) containing residues 99-496 was cloned
into pET28b and purified as described (Dian et al., 2020).

Full-length HsNMT2, AtNMT, PfNMT, and ScNMT can be expressed and purified
according to similar protocols as previously described (Castrec et al., 2018; Traverso, Giglione,
& Meinnel, 2013a).

238 2.3.3 IpaJ protease

IpaJ (EC:3.4.22) is a cysteine protease displaying tight cleavage specificity for myristoylglycine-starting peptides that hydrolyzes the peptide bond immediately following the glycine residue (Burnaevskiy et al., 2013; Burnaevskiy, Peng, Reddick, Hang, & Alto, 2015; Rivière et al., 2022). A scheme of the reaction catalyzed by IpaJ is provided in **Fig. 1C**.

A truncated (i.e., devoid of the N-terminal secretion peptide) and more soluble (3M) variant of the open reading frame of *Shigella flexneri* protease IpaJ is cloned into pETM30 as a fusion with a N-terminal His-tag and glutathione S-transferase (GST) as described (Rivière 246 et al., 2022). IpaJ is produced from Rosetta2-DE3pLysS cells. Bacteria are grown in 1 L of 2x 247 TY medium supplemented with kanamycin (50 μ g/mL) and chloramphenicol (34 μ g/mL) at 248 37°C under vigorous shaking. Protein overexpression is induced with 0.5 mM IPTG at 249 $OD_{600}=0.8$. Cells are transferred at 20°C and grown for 20 h. Cells are centrifuged at 5,000 x g and the pellet resuspended (10 mL/g) in lysis buffer (20 mM Tris pH 8.0, 0.2 M NaCl, 5 mM 250 251 2-mercaptoethanol, 5 mM imidazole, 5% glycerol). Cells are lysed with a sonicator (amplitude 252 50%, 10 s on and 30 s off) for 3 min at 4°C. The sample is then centrifuged at 40,000 x g (Rotor 253 JA25-50, Beckman Coulter) for 20 min and the pellet discarded. The supernatant is loaded on a Ni-IMAC-HisTrapTM FF 5 mL column (GE Healthcare) at 3 mL/min; elution is achieved 254 255 with a liner 0-0.5 M imidazole gradient run over 100 ml. Purified proteins are dialyzed using 256 Spectra-Por7 semi-permeable dialysis membranes (8 kDa cut-off; Thermo Fisher Scientific) 257 for 48 h against conservation buffer (20 mM Tris pH 8.0, 0.2 M NaCl, 5 mM DTT, 55% 258 glycerol) at 4°C. The sample is stored at -20°C.

259 2.4 Reagents

260 2.4.1 Fatty acyl derivatives

Myristoyl-CoA lithium salt (Sigma-Aldrich, M4414) MM = 977.9 g/mol; 5 mg diluted in
25.565 mL. Stock solutions (0.2 mM) are prepared in 10 mM sodium acetate, pH 5.6, and 1%
Triton X-100, except for MALDI analysis, where cholate is used instead of Triton to reduce
background (see below). The low pH prevents slow CoA hydrolysis.

80% pure myristoyl-CoA lithium salt (Sigma-Aldrich, M4414) MM = 977.9 g/mol; 5 mg
diluted in 0.511 mL in 50% DMSO (final concentration 10 mM), e.g., for use in crystallization
trials.

- Acetyl-CoA, >93% pure (Sigma-Aldrich, A2056).
- Myristic acid (Sigma-Aldrich, M3128).

- Alkynyl myristic acid (Myr-Alk; Click Chemistry Tools, 1164-100).
- Azido myristic acid (Myr-Az; Click Chemistry Tools, 1345-100).

• Radioactive myristoyl-CoA (³H or ¹⁴C), which must be ordered as a custom synthesis, e.g.,
from Selcia, Moravek Biochemicals Inc., Quotient Sciences, or ViTrax or prepared as

- described in §3.1 from radiolabeled myristic acid (Moravek Inc, MC118 or MT918).
- 275 2.4.2 Peptides
- 276 Custom peptides octapeptides of any sequence are all from GenScript Biotech (Rijswijk,277 Netherlands).
- 278 2.4.3 Reactants for gel imaging
- Pre-stained protein ladder 10-250 kDa (PageRuler Plus, Thermo Fisher, 26620).
- TAMRA-PEG3-azide (BroadPharm, BP-22479) for in-gel imaging alkyne-tagged proteins
- 281 by click chemistry. The TAMRA excitation peak corresponds to the Cy3 laser line and is fully
- 282 compatible with parallel Cy5 detection.
- TAMRA DBCO (Click Chemistry Tools, A131-5) is a reactive probe used for imaging
- alkyne-tagged biomolecules via a copper-free click reaction.
- Biotin-PEG3-Azide (Thermo Fisher Scientific, J64996.MB; Sigma-Aldrich, 762024).
- TAMRA-biotin-PEG3-azide (Click Chemistry Tools, 1048).
- AlexaFluor Streptavidin 635 (Thermo Fisher Scientific, S32364) for fluorescence detection
- 288 of proteins clicked with a biotin-PEG3-azide probe after blotting on PVDF membranes.
- ARF6-specific rabbit polyclonal antibody (Bethyl Laboratories, Inc; A305-238A).
- Beads coupled to Flag-tag antibody from the µMACS[™] DYKDDDDK Isolation Kit (Miltenyi
 Biotec).
- NMT inhibitor IMP-1088 (Cayman Chemical Company, 25366) or DDD85646 (Cayman
 Chemical Company, 13839).

294 **2.5 Buffer components**

- 295 2.5.1 For storage at room temperature
- MgCl₂ stock 100 mM q.s. 50 mL; MM = 292.24 g/mol; 1.0165 g in 50 mL.
- Triton X-100 10% q.s. 15 mL; dilute use 1.5 mL Triton X-100 solution (Sigma-Aldrich, 93443).
- Ethylenediaminetetraacetic acid 0.5 M (EDTA) q.s. 100 mL; MM = 203.3 g/mol (SigmaAldrich, 03609). Add 101.6 g in H₂O and dissolve, taking advantage of NaOH addition (high
 concentration or chips) to reach pH 8 and allow complete solubilization in 100 mL final
- 302 volume.
- 4x Laemmli buffer is 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol
 blue, and 0.125 M Tris HCl, pH 6.8.
- Phosphate Buffer Saline (PBS) buffer is 137 mM NaCl, 27 mM KCl, 10 mM Na₂PO₄, 18
 mM, K₂PO₄ and is adjusted to pH 7.4.
- 307 2.5.2 For storage at -20°C
- Bovine serum albumin (BSA, Sigma-Aldrich) 10 mg/mL q.s. 10 mL in H₂O; aliquots of 200
 μL.
- Dithiothreitol (DTT) 6.4 mM q.s. 20 mL; MM = 154.25 g/mol, 19.74 mg in 20 mL H₂O;
 prepare aliquots of 500 μL. Storage at -80°C is even better.
- Sodium acetate 10 mM/Triton X-100 1% solution: add sodium acetate 10 mM q.s. 100 mL
- 313 (82.03 mg acetate-Na (82.03 g/mol) in 100 mL H_2O , 1 mL Triton X-100; adjust to pH 5.6 with
- a few drops of acetic acid and NaOH. Aliquots of 2 mL can be prepared.

315

316 **3.** Preparation of noncommercial N-myristoyl protein or CoA derivatives

317 **3.1** Myristoyl-CoA and any unusual CoA acyl derivatives

This method was first established in the early 1990s (Devadas et al., 1992; Kishore et al., 1991). It involves acyl-CoA synthetase (ACS, **Fig. 1B**0.03 U/ μ L final concentration in a 100 μ L final volume consisting of 160 μ M fatty acid or a myristate derivative (radiolabeled or clickable), 1 mM CoA (from stock 5 mM), 5 mM ATP (from stock 20 mM), 3 mM DTT, 0.05 % Triton X-100, 5 mM Tris pH 7.4, 2.5 mM MgCl₂, and 50 μ M EGTA.

323 The enzyme catalyst (ACS, $0.03 \text{ U/}\mu\text{L}$ final) is added to start the reaction for 1 h at 37°C. 324 After 25 min, more than 50% of the myristate is already converted into myristoyl-CoA. This 325 is sufficient for further labeling of protein targets. The reaction product can be used as is and 326 without further purification in protein labeling experiments (see below).

Radioactive labeling may also be useful for imaging and band quantification of cell extracts
following pulse labeling with myristate. Radioactive imaging needs very long exposure times
(Berthiaume, Peseckis, & Resh, 1995). Click chemistry-based imaging using reactive
precursors may provide similar but faster results, although absolute quantification is less
convenient and reliable (see §4.4).

• Chemical synthesis of the azido derivative of Myristoyl-CoA (ω -Azido undecanoic acid CoA thioester) has been described (Heal, Wickramasinghe, Leatherbarrow, & Tate, 2008). The protocol can be applied to a variety of myristate analogs which organic synthesis methods are also available (Devadas et al., 1992).

336

337 **3.2** Myristoylated protein substrates

338 3.2.1 Fatty acid tagging of target proteins with NMT in vitro

The protocol originates from that previously set up for the myristoylation of two small GTPases, *A. thaliana* ARA6 (Boisson & Meinnel, 2003) and human ARF6 (Padovani, Zeghouf, Traverso, Giglione, & Cherfils, 2013). The purification of ARF6 from pET21-Arf6His6 to homogeneity is detailed in (Padovani et al., 2013).

• The final reaction volume is 1 mL with 25 μ M of protein of interest, 1 μ M HsNMT1, and 80 μ M myristoyl-CoA. The CoA donor can correspond to any fatty acyl derivative, such as those reported in §3.1 and originating from the labeling reaction described in this section. The reaction is run for 30 min at 30°C in 50 mM Tris pH 8.0, 1 mM MgCl₂, 0.2 mM EGTA, and 0.3 mM DTT. In the case of small G-proteins, addition of GTP (0.2 mM) has been shown to stimulate acylation rates comparable to GDP. ScNMT is less efficient than HsNMT1 or AtNMT.

The final product can be characterized by denaturing PAGE or mass spectrometry (see below,
Fig. 2 and Fig. 3)

• Use of click-reactive myristoyl-CoA can be a way to tag the protein and characterize it on gels using, for instance, DBCO- or azido-TAMRA (see below).

354 3.2.2 Myristoyl tagging in cell free translation systems

Insect cell-free protein synthesis from extracts of the *Spodoptera frugiperda* Sf21 cell line is an alternative to produce and tag the target protein considered *in vitro* (Suzuki et al., 2010). Coupled transcription and translation of any cDNA of interest cloned in a plasmid under the control of the T₇ promoter can be achieved with the TnT T7 Insect Cell Extract Protein Expression System (Promega, L1101). Radiolabeled or clickable myristate can be added to the reaction to follow protein myristoylation of the target by SfNMT (see §4.4).

Rabbit reticulocyte lysates (Promega, L4970) or wheat germ extracts (Promega, L4380)
may be used to take advantage of mammalian or plant NMT tagging (Deichaite, Casson, Ling,
& Resh, 1988; Yamauchi et al., 2010). *In vitro* transcribed mRNAs need to be produced first
and provided as translation templates (Utsumi et al., 2004).

365 3.2.3 Bacteria-driven target labeling

366 Like eukaryotes, bacteria express a methionine aminopeptidase (Giglione et al., 2004; Giglione, Fieulaine, & Meinnel, 2009). Nevertheless, bacteria do not possess a myristoylation 367 368 system equivalent to NMT, preventing genuine Gly-myristoylation (Deichaite et al., 1988; 369 Giglione & Meinnel, 2022; Knoll, Johnson, Bryant, & Gordon, 1995; Rudnick, Mcwherter, 370 Gokel, & Gordon, 1993). To allow target acylation in bacteria, one needs to (i) rely on 371 heterologous NMT expression and (ii) take advantage of the fact that prokaryotes possess both 372 a fatty acid import system (fadL) and ACS (fadD in E. coli, Fig. 1B). This allows bacteria to 373 import fatty acids from the growth medium and to transform them into acyl-CoA derivatives 374 (Giglione & Meinnel, 2022). Provided non-minimal cell extracts are added to the growth 375 medium - usually yeast extracts - myristoyl-CoA can therefore be made available in bacterial 376 cells for protein N-myristoylation by NMT. Nevertheless, without further supplementation, 377 bioavailable concentrations of free myristoyl-CoA are extremely low in bacteria, because C14 378 derivatives are very poorly represented in yeast and because acyl compounds are weakly 379 soluble in the absence of albumin, the natural scavenger of fatty acids in animal fluids (Giglione 380 & Meinnel, 2022). To promote significant myristoyl-CoA concentrations, myristate - diluted 381 from a 100-fold stock solution - can be supplied to bacteria prior to induction with IPTG at a 382 final concentration of 50 µM bound to 6 µM BSA (Franco, Chardin, Chabre, & Paris, 1995). 383 BSA has an average of seven myristate-binding sites (Giglione & Meinnel, 2022).

Myristoylation of any favorite target in bacteria is therefore feasible provided (i) the recombinant target gene is available and can be retrieved in the soluble fraction in, for example, *E. coli* cells; (ii) the NMT gene can be co-expressed with the target, for instance through either a compatible or a dual expression plasmid such as pETDuet-1 (Glück, Hoffmann, Koenig, & Willbold, 2010); and (iii) myristate or any derivative - including radioactive or clickable

compounds - is provided in the bacterial growth medium. This system was described early on using ScNMT and a recombinant murine protein kinase (Duronio et al., 1990). ScNMT is usually provided – for instance through the pBB131 plasmid – but appears less efficient than mammalian or plant NMTs. Complete Gly-myristoylation of HIV-1 Nef protein can be obtained with HsNMT1 (Glück et al., 2010).

Finally, having in hand a target gene easily purifiable by, for example, taking advantage of a C-terminal tag - such as ARF6-His in section 2.2.1 - is of benefit to further studies but it is not mandatory when studying issues related to acylation occurrence. The availability of specific antibodies and/or metabolic labeling with radioactive or clickable precursors is sufficient to conclude using approaches such as those described in the next section. Such investigations with ARF1 and ARF6 are described in volume 404 of this series (Ha, Thomas, Stauffer, & Randazzo, 2005).

401 3.2.4 Quality controls

402 • Denaturing gel electrophoresis is one first gross approach. It was noted early on that protein 403 acylation often promotes faster migration of the acylated product assessed by denaturing gel 404 electrophoresis (SDS-PAGE), for example for the yeast ADP-ribosylation factors ARF1/2 405 (Lodge et al., 1997) or human ARF6 (Fig. 2A). Therefore, comparison of the relative intensities 406 produced data on the acylation reaction yield. However, such faster migration is not universal 407 but only occurs more frequently than average, and it is not specific since it can sometimes be 408 reversed or absent for other proteins. Longer migration times on high-resolution gels may 409 improve the migration shift between the two species (Fig. 2B, lane 1). If a radioactive 410 derivative is used as the CoA donor, an autoradiogram is used to directly visualize the labeling. 411 If using a clickable fatty acyl donor (reaction conditions and details are provided in §4.4), 412 reactivity with any convenient fluorophore such as TAMRA coupled to an alkyl or azide reactive group for Cu(I)-catalyzed azide-alkyne click chemistry reactions (CuAAC) or strainpromoted azide-alkyne click chemistry reactions (SPAAC) is most useful, and fluorescence
overlapping with the blue staining may be a convenient tool for checking acylation (see Fig.
2C). The sample is separated by SDS-PAGE and the gel directly imaged on a fluorescence
imager. However, this approach is qualitative.

MALDI-TOF/TOF characterization of the purified product is a finer assessment of protein
myristoylation (see Fig. 3A-B) but it may be unsuitable for very large proteins (see §4.2).

420 4. Characterization of NMT-induced modifications on protein targets

421 4.1 General considerations

422 The rules of NMT-mediated Gly-myristoylation specificity have been investigated for 423 decades, and it occurs in about 2% of the human and A. thaliana (a dicot model plant) 424 proteomes (Castrec et al., 2018; Meinnel, 2022; Meinnel et al., 2020). Specificity was first 425 studied in detail for the yeast enzyme ScNMT (Bhatnagar, Ashrafi, Futterer, Waksman, & 426 Gordon, 2001; Towler, Gordon, Adams, & Glaser, 1988), which has similar specificity to other 427 NMTs but appears to disfavor some proteins with negatively charged residues located at 428 positions 8-9. Whether NMTs follow different rules in other organisms, including unicellular 429 organisms, is unknown. Nevertheless, studies on organisms such Toxoplasma gondii, 430 Plasmodium falciparum, or Leishmania donovani indicate similar overall rules (Brannigan et al., 2010; Broncel et al., 2020; Traverso et al., 2013a). Lys-myristoylation catalyzed by NMT 431 432 appears to act only as a post-translational modification of proteins starting with Gly-Lys 433 residues, including ARF6 (Rivière et al., 2022).

434 Studies aiming to define the full set of proteins targeted by NMT led to the application 435 of proteome-wide approaches with click chemistry tools together with state-of-the-art 436 electrospray ionization (ESI) mass spectrometry instruments. Detailed protocols and methods

have recently become available (Kallemeijn et al., 2021). Bioinformatics analyses based on
machine learning approaches on partial datasets, such as using support vector machines, are
also helping to complete the picture (Castrec et al., 2018; Madeo, Savojardo, Martelli, &
Casadio, 2022).

441 This section describes several methods focusing on in vitro approaches with selected 442 targets of interest, including full-length proteins or N-terminal-derived short peptides. 80% of 443 target proteins in the complete human proteome (Meinnel, 2022), plants, and probably any 444 organism are soluble cytosolic proteins of average length less than 40 kDa. This makes 445 overexpression and further purification from bacterial cells to homogeneity in sufficient 446 quantities for further studies including MS easy. With short peptides, the MS approach is often 447 most useful for deciphering the actual modification state, including the type of modification. 448 This can be difficult to establish, especially for proteins starting with Gly-Lys residues – both 449 amino groups are potentially acylated - such as for ARF6. In some cases, and with longer 450 peptides or full-length putative target proteins, additional approaches are needed. We also 451 introduce in this context the IpaJ pipeline (Fig. 3; (Rivière et al., 2022)) and click chemistry-452 based approaches.

453 4.2 MALDI mass spectrometry

454 4.2.1 Main outlines

• 300 μ L of a mixture containing 50 mM Tris (pH 8.0), 0.193 mM EGTA, 1 mM MgCl₂, 1 mM DTT, 5 μ M sodium cholate, 40 μ M Myr-CoA solution (stock solution 0.2 mM Myr-CoA, 10 mM sodium acetate, 2.5 μ M sodium cholate), 0.5 μ M NMT, and 100 μ M of synthetic peptide or full-length protein are pre-incubated at 30°C. The myristoylation reaction is followed over time by collecting 10 μ L samples further diluted in 90 μ L of water/acetonitrile (90/10) solution. • The different samples are then diluted five times in the matrix solution of 5 mg/mL (i) α -462 cyano-4-hydroxycinnamic acid solubilized in water/acetonitrile/formic acid (50/50/0.1%) for 463 peptides or (ii) 3,5-dimethoxy-4-hydroxycinnamic acid in water/acetonitrile/formic acid 464 (50/50/0.1%) for whole proteins.

• 1 μ L of each dilution is spotted on a metal target and dried.

MS and MS/MS spectra from each sample are acquired with a MALDI-TOF/TOF instrument
in positive ion mode.

Survey scans are performed using delayed extraction (390 ns) in reflector mode for a total of
15,000 shots. MS/MS scans are operated with a collision energy of 1 kV. Peptide and fragment
mass tolerances are set at 10 ppm and 0.8 Da, respectively.

Mass spectra are analyzed with PeakView 1.2 software (AB Sciex LLC). The default
threshold in MS/MS peak labeling and finding is 5% and centroid height percentage is 50%,
as recommended by the manufacturer. MS/MS deviations from theoretical values are on
average less than 0.03 Da.

475 *4.2.2* Notes

For MALDI mass spectrometry, Triton X-100 needs to be avoided as a detergent. The
steroid-based anionic detergent sodium cholate substitutes for the Triton X-100 used in enzyme
kinetics studies.

MS/MS analysis allowing accurate analysis of the modification state can be achieved on
short peptides. Assignments of peptides with non-natural amino acids can also be performed
using ProteinProspector v6.2.2 (<u>https://prospector.ucsf.edu/prospector/mshome.htm</u>)
(Chalkley, Baker, Medzihradszky, Lynn, & Burlingame, 2008). Theoretical mass values of all
fragments are double-checked at <u>https://web.expasy.org/peptide_mass/</u>.

484 • Demonstration of Gly-myristoylation analysis of tryptic fragments from full-length proteins 485 is feasible by MALDI MS/MS (Suzuki et al., 2006; Suzuki et al., 2010). 486 • MALDI MS on proteins larger than 30 kDa is challenging. In this case, electrospray 487 ionization (ESI) MS is better suited. • MALDI promotes one singly charged ion, usually H⁺ ([M+H]⁺), but also sometimes doubly 488 489 charged ions, triply charged ions, and Na⁺ adducts (+23 Da). Due to multiple charge values for 490 each molecular mass induced by ESI, mass spectra must be deconvoluted (Xu et al., 2018). 491 • MALDI MS also works fine with short peptides (see an example in Figure 2, Chapter 26, 492 this volume (Rivière, Monassa, Giglione, & Meinnel, 2023) and (Rivière et al., 2022)). 493 • Controls in the absence of myristoyl-CoA or catalysts such as NMT need to be run and 494 analyzed by MS in parallel. 495 • The monoisotopic mass is used as a mass reference with highly pure, chemically-synthesized 496 peptides. With purified proteins, the average mass is taken into account. The mass at the top of 497 the mass peak is always considered. 498 • With high molecular weight proteins such as ARF6-His, determination of the average mass 499 by MALDI is more accurate by taking the m/z=2 state charge into account, even though less 500 intense and not always available (Fig. 3).

Standard deviation values are obtained after several independent measurements of the mass
of the same sample.

503 4.3 The NMT/IpaJ pipeline

504 This semi-quantitative assay was established to decipher the type of NMT-catalyzed 505 modification, e.g., Gly- or Lys-myristoylation (Rivière et al., 2022). The complete pipeline -506 based on the high selectivity of IpaJ for myristoyl-glycine-starting proteins - is described in

- detail in Fig. 3 for a full-length protein (ARF6) but can be equally applied to short peptides, as
 reported (Rivière et al., 2022).
- The peptide (100 μ M) is first incubated for 1 h in the presence of 0.5-1 μ M HsNMT1 or 510 HsNMT2 (T1). The buffer is the same as for NMT activity measurements but contains 5 μ M 511 cholate instead of Triton X-100.
- Full IpaJ cleavage conditions involve further incubation at 20°C for 1 h in the presence of
 10 μM IpaJ-3M and 0.1 mM DTT (T2).
- 1-5 μ M HsNMT1 is finally added for another 1 h at 30°C to ensure full acylation of all possible substrates (T3). T0 corresponds to the T3 timepoint (3 h) with the peptide diluted in the incubation buffer but in the absence of any enzyme.
- 517 4.4 Click chemistry-based protein imaging
- 518 *4.4.1* Overview

519 Click chemistry approaches can be achieved if the target protein has previously been 520 tagged with a reactive acyl myristate *in vitro*. This is detailed in §3.2.

521 An alternative to such in vitro analysis is often required to obtain in cellulo-relevant 522 information on the actual myristoylation state of the target protein. This requires prior cell 523 labeling with a myristate precursor and applies to proteins expressed in cell-free (see §3.2.2), 524 bacterial (see §3.2.3) or mammalian cells systems (see §4.4.2). This precursor is metabolized 525 into a CoA derivative, which NMT can then use to acylate proteins (see details in (Giglione & 526 Meinnel, 2022)). To identify the tagged protein originating from in cellulo studies, it can be 527 either immunoprecipitated with another C-terminal tag if a transgene is used or with specific -528 preferentially polyclonal - antibodies. In any case, PAGE analysis followed by specific imaging 529 is often used to detect the target protein. This requires a click or biorthogonal compatible fluorophore such as alkyne- or DBCO-TAMRA derivatives, depending on the myristate label 530

531 chosen as the precursor for protein labeling. One major challenge is to ensure that the 532 fluorescent signal arises from the selected target if not purified beforehand by 533 immunoprecipitation. Assessing the correlation between migration and labeling is one 534 approach to ensure this but is only indicative of the actual modification state.

If myristate reactivity is first challenged with a biotin derivative (see §2.4.3), 535 536 identification of the merged fluorescence originating from a mixture of (i) a fluorescent-537 streptavidin probe (e.g., labeled with a Cy3 fluorophore) and (ii) the specific antibody revealed 538 with a secondary antibody conjugated to a compatible fluorophore (see §2.4, e.g., Cy5) on the 539 same immunoblot may be more accurate (see Figure 2 in (Neopane et al., 2022)). However, 540 the associated data, even with unambiguous merging of fluorescent signals, does not 541 definitively prove the myristoylation state. Therefore, to assess this in vivo myristoylation, 542 specific NMT inhibitors such as IMP-1088 or DDD85646 can be used (2 μ M) to demonstrate 543 block of the modification (Kosciuk et al., 2020; Mousnier et al., 2018). An additional very 544 strong proof may be possible by comparing overexpressing and control samples, i.e., increased 545 intensity of the signal observed upon overexpression of the target protein. Fig. 2D illustrates 546 this approach with ARF6 in human cells.

547 4.4.2 In cellulo labeling procedures with acyl precursors

HEK293 cells are maintained at 37°C in 5% CO₂ in Dulbecco's modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal calf serum, 100 U/mL penicillin
(Gibco), 100 U/mL streptomycin sulfate, 2 mM L-glutamine, and a cocktail of non-essential
amino acids.

Cells are transfected with the pJAF211 plasmid in Lipofectamine 3000 (Thermo Fisher
 Scientific) according to the manufacturer's instructions to express ARF6-Flag. After 3 hours
 of transfection, the medium is renewed with fresh culture medium, to which 20-40 µM alkyne

555 myristate (Alk-myristate) or unmodified myristate is added. After 18 to 24 h of culture, the 556 cells are harvested and lysed with a lysis buffer (PBS pH 7.4, 0.1% SDS, and 1% Triton X-557 100) and a protease inhibitor cocktail (cOmplete ULTRA Tablets, Mini, EDTA-free, 558 EASYpack). Protein concentration is determined with the standard Bradford assay (Bio-Rad).

559 4.4.3 In-gel imaging

• Cell lysates are diluted to 2 μ g/ μ L total protein in lysis buffer. A mix of click reagent is prepared and added to the lysates to obtain the following final concentrations: 40 μ g total protein, 100 μ M azide probe (TAMRA and/or biotin); 1 mM CuSO4; 1 mM TCEP (tris(2carboxyethyl)phosphine); and 100 μ M THPTA (tris(3-hydroxypropyltriazolylmethyl)amine). After 1 h of incubation at room temperature (21°C) with shaking at 12 Hz, the reaction is stopped by adding EDTA to 5 mM final concentration.

• For direct fluorescence analysis following SDS-PAGE when the reactive probe is coupled to a TAMRA fluorophore, the products of the click reaction are denatured and diluted with 1/4 volume of 4x Laemmli buffer and then migrated on 12% SDS-PAGE. The metabolically labeled proteins are visualized on the gels with an imager using Cy3 filters (λ_{ex} =532 nm; λ_{em} =610 nm).

• N-terminal protein lipidations in cell extracts mostly lead to two types of acylations, 571 572 myristoylation (C14) and palmitoylation (C16). These modification differ by the nature of their 573 linkage to the protein, amide or ester, respectively. Distinction between the two types of 574 modifications may be challenging because of metabolic interconversions of fatty acid 575 precursors (Giglione & Meinnel, 2022). The high susceptibility and effective cleavage of the 576 ester bond in alkaline conditions - obtained for instance with KOH (0.1 M in methanol) for 4 577 h at room temperature (Bizzozero, 1995) - is a relevant approach to check that the detected 578 acylation does arise from N-terminal amidation and is most likely catalyzed by NMT.

579 4.4.4 Immunoprecipitation

580 • One milligram of total protein from cell lysates is combined with 5 µg of target antibody and 581 adjusted to 500 µL in IP-MS Cell Lysis Buffer (Pierce MS-compatible Magnetic IP Kit, 582 Thermo Fisher Scientific) and then incubated overnight with shaking. The remaining procedure 583 is carried out according to the manufacturer's protocol. In brief, 0.25 mg of magnetic beads 584 coated with A/G proteins are washed in the lysis buffer and then incubated with the 585 antibody/antigen mixture for 1 h at room temperature. The mixture is then washed 5 times and 586 the antigens eluted, and the supernatant recovered and dried in a concentrator under vacuum 587 (SpeedVac).

Immunoprecipitation is carried out using the µMACS™ DYKDDDDK Isolation Kit
 (Miltenyi Biotec) according to the manufacturer's protocol.

The tagged protein is visualized with specific antibodies. An example of ARF6 detection
with Flag-tag antibodies is shown in Fig. 2E.

• To increase the concentration, protein samples can be subjected to methanol:chloroform (4:1) precipitation and centrifuged for 5 min at 13,000 x g. The upper aqueous phase is discarded to leave the interface layer containing intact protein precipitate. 450 μ L methanol is added to the tube, vortexed, and centrifuged for 5 min at 13,000 x g to pellet the protein. The pellet is washed with 450 μ L methanol to remove residual reaction components. The pellets are allowed to air dry. The dried protein precipitates can be resolubilized in Laemmli sample buffer for further SDS-PAGE analysis.

599 4.4.5 Fluorescence imaging after immunoblotting

Proteins separated by 12-15% SDS-PAGE are transferred (25 mM Tris; 190 mM glycine;
20% MetOH) onto a polyvinylidene fluoride (PVDF) membrane at 4°C 30 V overnight. The

602 PVDF membrane is incubated and blocked in 3% TBST BSA (20 mM Tris pH 7.5; 150 mM
603 NaCl; 0.1% Tween 20; 3% BSA) for 90 min at room temperature.

The membrane is incubated with the primary – here anti-Flag or anti-ARF6 - antibody diluted
1:1000 according to the manufacturer's recommendations, before being washed 5 times in
TBST BSA 1%.

The membrane is incubated with a secondary anti-IgG conjugate antibody tagged with a Cy5
fluorophore and the streptavidin–Cy3 derivative diluted at 1:10,000 in the blocking buffer at
4°C overnight.

• Imaging is performed with both the Cy3 and Cy5 channels and the fluorescence merged as 611 required.

612 5. Structural studies of NMT and its complexes with substrates and 613 products

614 5.1 Structural overview

615 NMTs are made up of a two-GNAT core (Meinnel et al., 2020). The N-terminal domain 616 is of varying length and is not folded. High resolution crystal structures are available for NMTs 617 from Aspergillus fumigatus (Shimada, Suzuki, & Katakura, 2015), Candida albicans (Bhatnagar et al., 1998), Homo sapiens (both forms and various isoforms (Castrec et al., 2018; 618 619 Thinon et al., 2014)), Leishmania donovani and major (Brannigan et al., 2010; Frearson et al., 620 2010), Plasmodium vivax (Goncalves et al., 2012) and Saccharomyces cerevisiae (Wu et al., 621 2007). HsNMT1's longest structures start at residue 99, which includes a crucial B'A' helix (Castrec et al., 2018). Many HsNMT1 structures start at residue 109 or 116. HsNMT2 crystal 622 623 structures start at residues 112 (4C2X, (Thinon et al., 2014)) and 116 (6PAU (Kosciuk et al., 624 2020)) and miss the important element involved in a major conformational change contributing 625 to product release (Dian et al., 2020).

AlphaFold software predictions (Jumper et al., 2021) of the structure of several NMTs are available at UniProt (<u>https://www.uniprot.org/</u>). Interestingly, the AlphaFold predictions of HsNMT, PvNMT and AtNMT structures suggest that there is an additional alpha helix at the beginning of the folded GNAT domain (residues Asn82 in HsNMT1, Met88 in HsNMT2, Asp27 in PvNMT, Leu31 in AtNMT1), a structure hitherto not identified by crystallographic approaches (**Fig. 4A** for both HsNMTA and HsNMT2; see also AF-Q9LTR9-F1 and AF-A0A1G4HIY1-F1 for AtNMT1 and PvNMT at <u>https://alphafold.com/</u>).

Recent investigations have provided details of NMTs in action with their two substrates.Below are the approaches used to capture such short-lived complexes.

635 **5.2** Crystallization and structure determination

636 5.2.1 General crystallization conditions

In recent studies, HsNMT1(*s*) was used to solve the structures of the complexes with
various substrate peptides (Castrec et al., 2018; Dian et al., 2020; Kosciuk et al., 2020; Rivière
et al., 2022). The associated PDB entries are indicated in the published papers.

640 Suitable crystals of HsNMT1:MyrCoA:peptide substrates were obtained by co-641 crystallization using the hanging-drop vapor diffusion method at 20°C in the crystallization 642 conditions previously described (Castrec et al., 2018; Dian et al., 2020). Briefly, crystallization droplets are formed by mixing 2 µL of the of HsNMT1:MyrCoA:peptide complex (ratio 643 1:1.5:1.5) at 6-9 mg/mL with 2 μ L of the precipitant solution containing either 0.1 M MgCl₂, 644 645 0.2 M NaCl, 0.1 M sodium citrate pH 5.6, and 18-24% (w/v) PEG 6K or 0.1 M sodium acetate 646 pH 4.6 and 18-24% (w/v) PEG 6K. Crystals are cryoprotected in the reservoir solution supplemented with 15% (v/v) glycerol and flash cooled in liquid nitrogen. 647

648 5.2.2 Obtaining crystals of NMT in complex with reactants or reaction intermediates

GNATs use a sequential ordered Bi-Bi mechanism involving binding first to the CoA
derivative and then to the peptidyl target (Salah Ud-Din, Tikhomirova, & Roujeinikova, 2016).
This also applies to NMTs and has been demonstrated for ScNMT and HsNMT1 (Rocque,
Mcwherter, Wood, & Gordon, 1993; Rudnick et al., 1991). This feature needs to be taken into
account in crystallographic trials.

654 • CoA derivative complexes. NMT crystal structures – as is the case for most GNATs – are most often determined in complex with their cognate CoA derivative. Crystals devoid of the 655 656 CoA derivative are rarely obtained. This probably originates from the structural remodeling of 657 the CoA binding site upon binding. When overexpressed in *E. coli*, the acetyl-CoA derivative 658 tightly binds to GNATs and it appears unnecessary to add it. Nevertheless, myristoyl-CoA is 659 not available, as fatty acyl CoA derivatives do not accumulate in E. coli (Giglione & Meinnel, 660 2022; Meinnel, 2022). The growth medium can be supplemented with myristate, as it can be 661 converted in cellulo by ACS in bacteria (Fig. 1B). Myristoyl-CoA can also be added in 662 crystallization trials.

Peptidyl complexes. Multiple factors have significant impact on the success in obtaining
crystals of intermediates. From our experience gained while generating the data reported in
(Dian et al., 2020) with peptides X (GNCSFSKRRA), Y (GSNKSKPK), U (*ac*-GKSFSKPR),
and V (*ac*-KSFSKPR), these include:

- Soaking (peptide Y) instead of co-crystallization (peptide X) to reduce reaction time. It is
tempting to say that a 15 min soak used to solve the complex with peptide Y seems to have
been sufficient to pick up the intermediate, while co-crystallization with peptide X gave time
for the reaction to occur;

Both low and different pHs of the precipitant solutions (pH 4.6 with peptide Y and pH 5.6
with peptide X, (Dian et al., 2020)) significantly contributed to slowing down the NMT
reaction (optimum pH is 8.0);

- Nature of the two peptides for which NMT displays different catalytic efficiencies;

- Crystal trials must be performed under many different conditions (i.e., different peptides,
different peptide concentrations, different soaking times), and most of them will remain
inconclusive (e.g., no crystal, poor resolution, no intermediate). Only successful datasets are
presented in publications, probably representing the outcome of many trials. We also observed
that several crystals need to be collected from the same batch to finally observe a few of them
showing reaction intermediates.

681 5.2.3 Dataset collection, structure resolution, and refinement

682 Complete X-ray datasets of complexes are collected at 100*K*, a single wavelength from
683 a single crystal, at synchrotron facilities such as the French National Synchrotron Facility
684 (SOLEIL) PROXIMA-1 or PROXIMA-2 beamlines or at the European Radiation Synchrotron
685 Facility (ESRF) with the ID30A1 and ID30A3 beamlines.

• Datasets are integrated with XDS (Kabsch, 1993) and scaled and reduced using AIMLESS
from the CCP4 package (Evans & Murshudov, 2013). For crystals suffering from anisotropic
diffraction, data are processed with STARANISO on unmerged data (Tickle et al., 2018) before
AIMLESS data reduction.

690 • Crystals of HsNMT1 complexes belong essentially to the space group $P2_12_12$ with similar 691 unit cell parameters, except for some belonging to C2 with distinct unit cell parameters. In both 692 space groups identified, unit cells contain two NMT molecules per asymmetric unit. Structure 693 resolution was accomplished in all cases using the molecular replacement method and solved 694 using PHASER (Mccoy et al., 2007) and the HsNMT1:MyrCoA:peptide ternary complex 695 (PDB entry 509T or 6SK2) as a search model. The structure of AN was solved using MOLREP 696 (Vagin & Teplyakov, 1997) and protein coordinates of HsNMT1:MyrCoA (PDB entry 509T) 697 as a search model.

698 • Structures are subjected to alternating refinement cycles using PHENIX and manual model 699 building using COOT (Adams et al., 2010; Emsley, Lohkamp, Scott, & Cowtan, 2010; 700 Murshudov et al., 2011). Good quality electron density maps enable the refinement of substrate 701 peptide, reaction intermediate, and reaction product molecules bound to HsNMT1 in each complex. Chemical compound libraries are generated using the PRODRG server (Schuttelkopf 702 703 & Van Aalten, 2004) in combination with eLBOW from the PHENIX suite. The geometry of 704 the final models is validated using MOLPROBITY (Chen et al., 2010). Figures are generated 705 using PYMOL (DeLano Scientific LLC, http://pymol.sourceforge.net/).

• Omit electron density maps can be calculated using PolderMap (Liebschner et al., 2017)
707 from the Phenix suite after omitting the peptide of each active site and excluding the bulk
708 solvent around the omitted region (Fig. 4B).

• Ball and stick representations in 2D are a good way to challenge and compare active site 710 interactions (Fig. 4C)

711 6. Conclusions and future prospects

Here we report a series of multiscale biochemical analyses that allow the capture and fine 712 713 definition of NMT catalysis and the validation of putative targets. This permits not only time 714 and space investigation but also challenging substrate selectivity experiments based on the 715 chemical choice and specificity provided by this unique family of catalysts. This exemplifies 716 the remarkable fluidity of the reaction catalyzed in vitro by NMTs. Other - mostly click 717 chemistry-based - methods are available for fine characterization of myristoylation at the cellular proteome level (see Chapter 24 by H. Lin et al. in this volume or (Kallemeijn et al., 718 719 2021)). Kinetic analysis of myristoylation by NMTs of octapeptides derived from actual 720 protein N-termini have been validated as a relevant and robust approach to contribute to 721 completing this effort at proteome scales (Boisson, Giglione, & Meinnel, 2003; Castrec et al.,

2018; Meinnel, 2022; Traverso et al., 2013a). Such methods are detailed in Chapter 26 in this
volume (Rivière et al., 2023).

724 Future progress in biochemical characterization will need to better address the acylation 725 yield (i.e., the ratio of each N-terminal acylation state to the total amount of a given protein) of each target, as it likely varies from one physiological condition to another. With differences in 726 727 myristoylation, the overall subcellular localization of the same target changes and most likely 728 favors different functions of the target. Therefore, investigation of the myristoylation yield on 729 a maximum number of targets - preferentially not overproduced in cellulo - will be required in 730 the future. Although such approaches exist in the case of N-terminal acetylation (Bienvenut, 731 Giglione, & Meinnel, 2015, 2017; Bogaert & Gevaert, 2020), this is not yet available for NMT 732 targets. This approach will probably need to enrich the N-terminal peptides without loss of the 733 most hydrophobic ones, including N-myristoylated peptides. Unfortunately, currently available 734 click-based approaches are not directly suited to this purpose, as they lead to the selection of 735 only the myristoylated state and the loss of all other isoforms.

736

737 Acknowledgements

We thank the I2BC proteomic platform SICaPS for productive and collaborative interactions over the past decade. We thank the French National Synchrotron Facility (SOLEIL) for providing the synchrotron radiation facilities and the staff of the PROXIMA-1 & -2 beamlines and the European Synchrotron Radiation Facility (ESRF) staff for help with data collection. We acknowledge David Cornu, Flaria El Khoury, Lucile Jomat, Jean-Pierre Le Caer, Virginie Redeker, and Laila Sago for their respective inputs in the setting of the various approaches presented in this manuscript.

745

746 Funding

747 This work was supported by French National Research Agency (ANR) DynaMYT (ANR-748 20-CE44-0013) and Fondation ARC (ARCPJA32020060002137) grants to TM. This work has 749 benefited from the support from a French State grant (Saclay Plant Sciences, reference n° 750 ANR-17-EUR-0007, EUR SPS-GSR) under a France 2030 program (reference n° ANR-11-751 IDEX-0003), from the I2BC crystallization platform supported by FRISBI (ANR-10-INSB-752 05-01), and from the facilities and expertise of the I2BC proteomic platform SICaPS, supported 753 by IBiSA, Ile de France Region, Plan Cancer, CNRS and Paris-Sud University. FR was 754 supported by grants from Région Ile-de-France (17012695) and Fondation pour la Recherche 755 Médicale (FDT202001010779).

756

757 **References**

- Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., et al. (2010).
 PHENIX: a comprehensive Python-based system for macromolecular structure
 solution. *Acta Crystallographica Section D*, *66*, 213-221.
- Berthiaume, L., Peseckis, S. M., & Resh, M. D. (1995). Synthesis and use of iodo-fatty acid
 analogs. *Methods in Enzymology*, 250, 454-466.
- Bhatnagar, R. S., Ashrafi, K., Futterer, K., Waksman, G., & Gordon, J. I. (2001). Biology and
 enzymology of protein N-myristoylation. In F. Tamanoi & D. S. Sigman (Eds.), *The Enzymes* (Vol. XXI (Protein lipidation), pp. 241-286). San Diego: Academic Press.
- 766 Bhatnagar, R. S., Futterer, K., Farazi, T. A., Korolev, S., Murray, C. L., Jackson-Machelski,
- E., et al. (1998). Structure of N-myristoyltransferase with bound myristoylCoA and
 peptide substrate analogs. *Nature Structural Biology*, *5*, 1091-1097.
- Bienvenut, W. V., Giglione, C., & Meinnel, T. (2015). Proteome-wide analysis of the amino
 terminal status of Escherichia coli proteins at the steady-state and upon deformylation
 inhibition. *Proteomics*, 15, 2503-2518.

- Bienvenut, W. V., Giglione, C., & Meinnel, T. (2017). SILProNAQ: a convenient approach for
 proteome-wide analysis of protein N-termini and N-terminal acetylation quantitation.
 Methods in Molecular Biology, 1574, 17-34.
- Bizzozero, O. A. (1995). Chemical analysis of acylation sites and species. *Methods in Enzymology*, 250, 361-379.
- Bogaert, A., & Gevaert, K. (2020). Protein amino-termini and how to identify them. *Expert Review of Proteomics*, 17, 581-594.
- Boisson, B., Giglione, C., & Meinnel, T. (2003). Unexpected protein families including cell
 defense components feature in the N-myristoylome of a higher eukaryote. *Journal of Biological Chemistry*, 278, 43418-43429.
- Boisson, B., & Meinnel, T. (2003). A continuous assay of myristoyl-CoA:protein Nmyristoyltransferase for proteomic analysis. *Analytical Biochemistry*, 322, 116-123.
- Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram
 quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry*, 72, 248-254.
- 787 Brannigan, J. A., Smith, B. A., Yu, Z., Brzozowski, A. M., Hodgkinson, M. R., Maroof, A., et
- al. (2010). N-myristoyltransferase from Leishmania donovani: structural and functional
 Characterisation of a potential drug target for visceral Leishmaniasis. *Journal of Molecular Biology, 396*, 985-999.
- 791 Broncel, M., Dominicus, C., Vigetti, L., Nofal, S. D., Bartlett, E. J., Touquet, B., et al. (2020).
- Profiling of myristoylation in Toxoplasma gondii reveals an N-myristoylated protein
 important for host cell penetration. *eLife*, *9*, e57861.
- Burnaevskiy, N., Fox, T. G., Plymire, D. A., Ertelt, J. M., Weigele, B. A., Selyunin, A. S., et
 al. (2013). Proteolytic elimination of N-myristoyl modifications by the Shigella
 virulence factor IpaJ. *Nature*, 496, 106-109.

- Burnaevskiy, N., Peng, T., Reddick, L. E., Hang, H. C., & Alto, N. M. (2015). Myristoylome
 profiling reveals a concerted mechanism of ARF GTPase deacylation by the bacterial
 protease IpaJ. *Molecular Cell*, 58, 110-122.
- Casey, P. J., & Buss, J. E. (1995). Lipid modifications of proteins. In P. J. Casey & J. E. Buss
 (Eds.), *Methods in Enzymolology* (Vol. 250, pp. 754).
- 802 Castrec, B., Dian, C., Ciccone, S., Ebert, C. L., Bienvenut, W. V., Le Caer, J.-P., et al. (2018).
 803 Structural and genomic decoding of human and plant myristoylomes reveals a
 804 definitive recognition pattern. *Nature Chemical Biology*, *14*, 671-679.
- 805 Chalkley, R. J., Baker, P. R., Medzihradszky, K. F., Lynn, A. J., & Burlingame, A. L. (2008).
- 806 In-depth analysis of tandem mass spectrometry data from disparate instrument types.
 807 *Molecular & Cellular Proteomics*, 7, 2386-2398.
- Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G.
 J., et al. (2010). MolProbity: all-atom structure validation for macromolecular
 crystallography. *Acta Crystallographica Section D*, 66, 12-21.
- Bil Deichaite, I., Casson, L. P., Ling, H. P., & Resh, M. D. (1988). In vitro synthesis of pp60v-src:
 myristylation in a cell-free system. *Molecular and Cellular Biology*, *8*, 4295-4301.
- Bevadas, B., Lu, T., Katoh, A., Kishore, N. S., Wade, A. C., Mehta, P. P., et al. (1992).
 Substrate specificity of Saccharomyces cerevisiae myristoyl-CoA: protein Nmyristoyltransferase. Analysis of fatty acid analogs containing carbonyl groups,
 nitrogen heteroatoms, and nitrogen heterocycles in an in vitro enzyme assay and
 subsequent identification of inhibitors of human immunodeficiency virus I replication. *Journal of Biological Chemistry, 267*, 7224-7239.
- Bian, C., Pérez-Dorado, I., Rivière, F., Asensio, T., Legrand, P., Ritzefeld, M., et al. (2020).
 High-resolution snapshots of human N-myristoyltransferase in action illuminate a

- 821 mechanism promoting N-terminal Lys and Gly myristoylation. *Nature* 822 *Communications*, *11*, 1132.
- Dümmler, A., Lawrence, A. M., & de Marco, A. (2005). Simplified screening for the detection
 of soluble fusion constructs expressed in E. coli using a modular set of vectors. *Microbial Cell Factories*, 4, 34.
- Buronio, R. J., Jackson-Machelski, E., Heuckeroth, R. O., Olins, P. O., Devine, C. S.,
 Yonemoto, W., et al. (1990). Protein N-myristoylation in Escherichia coli:
 reconstitution of a eukaryotic protein modification in bacteria. *Proceedings of the National Academy of Sciences*, 87, 1506-1510.
- Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010). Features and development of
 Coot. *Acta Crystallographica Section D*, *66*, 486-501.
- 832 Enríquez-Flores, S., De la Mora-De la Mora, J. I., Flores-López, L. A., Cabrera, N., Fernández-
- Lainez, C., Hernández-Alcántara, G., et al. (2022). Improved yield, stability, and
 cleavage reaction of a novel tobacco etch virus protease mutant. *Applied Microbiology and Biotechnology*, *106*, 1475-1492.
- Evans, P. R., & Murshudov, G. N. (2013). How good are my data and what is the resolution? *Acta Crystallographica Section D*, 69, 1204-1214.
- Franco, M., Chardin, P., Chabre, M., & Paris, S. (1995). Myristoylation of ADP-ribosylation
 factor 1 facilitates nucleotide exchange at physiological Mg2+ levels. *Journal of Biological Chemistry*, 270, 1337-1341.
- 841 Frearson, J. A., Brand, S., McElroy, S. P., Cleghorn, L. A., Smid, O., Stojanovski, L., et al.
- 842 (2010). N-myristoyltransferase inhibitors as new leads to treat sleeping sickness.
 843 *Nature, 464*, 728-732.

- Frottin, F., Martinez, A., Peynot, P., Mitra, S., Holz, R. C., Giglione, C., et al. (2006). The
 proteomics of N-terminal methionine cleavage. *Molecular & Cellular Proteomics*, 5,
 2336-2349.
- Giglione, C., Boularot, A., & Meinnel, T. (2004). Protein N-terminal methionine excision. *Cellular and Molecular Life Sciences, 61*, 1455-1474.
- Giglione, C., Fieulaine, S., & Meinnel, T. (2009). Cotranslational processing mechanisms:
 towards a dynamic 3D model. *Trends in Biochemical Sciences*, *34*, 417-426.
- Giglione, C., & Meinnel, T. (2022). Mapping the myristoylome through a complete
 understanding of protein myristoylation biochemistry. *Progress in Lipid Research, 85*,
 101139.
- Glück, J. M., Hoffmann, S., Koenig, B. W., & Willbold, D. (2010). Single vector system for
 efficient N-myristoylation of recombinant proteins in E. coli. *PloS One*, *5*, e10081.
- 856 Goncalves, V., Brannigan, J. A., Whalley, D., Ansell, K. H., Saxty, B., Holder, A. A., et al.
- 857 (2012). Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening,
 858 synthesis, and structural characterization of their binding mode. *Journal of Medicinal*
- 859 *Chemistry*, 55, 3578-3582.
- Gordon, J. I., Duronio, R. J., Rudnick, D. A., Adams, S. P., & Gokel, G. W. (1991). Protein Nmyristoylation. *Journal of Biological Chemistry*, *266*, 8647-8650.
- Ha, V. L., Thomas, G. M., Stauffer, S., & Randazzo, P. A. (2005). Preparation of myristoylated
 Arf1 and Arf6. *Methods in Enzymology*, 404, 164-174.
- Heal, W. P., Wickramasinghe, S. R., Leatherbarrow, R. J., & Tate, E. W. (2008). N-Myristoyl
 transferase-mediated protein labelling in vivo. *Organic and Biomolecular Chemistry*,
 6, 2308-2315.
- Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2021).
 Highly accurate protein structure prediction with AlphaFold. *Nature*, *596*, 583-589.

- Kabsch, W. (1993). Automatic processing of rotation diffraction data from crystals of initially
 unknown symmetry and cell constants. *Journal of Applied Crystallography, 26*, 795871 800.
- Kallemeijn, W. W., Lanyon-Hogg, T., Panyain, N., Goya Grocin, A., Ciepla, P., MoralesSanfrutos, J., et al. (2021). Proteome-wide analysis of protein lipidation using chemical
 probes: in-gel fluorescence visualization, identification and quantification of Nmyristoylation, N- and S-acylation, O-cholesterylation, S-farnesylation and Sgeranylgeranylation. *Nature Protocols, 16*, 5083-5122.
- Kapust, R. B., Tözsér, J., Fox, J. D., Anderson, D. E., Cherry, S., Copeland, T. D., et al. (2001).
 Tobacco etch virus protease: mechanism of autolysis and rational design of stable
 mutants with wild-type catalytic proficiency. *Protein Engineering, Design and Selection, 14*, 993-1000.
- Kishore, N. S., Lu, T. B., Knoll, L. J., Katoh, A., Rudnick, D. A., Mehta, P. P., et al. (1991).
 The substrate specificity of Saccharomyces cerevisiae myristoyl-CoA:protein Nmyristoyltransferase. Analysis of myristic acid analogs containing oxygen, sulfur,
 double bonds, triple bonds, and/or an aromatic residue. *Journal of Biological Chemistry*, 266, 8835-8855.
- Knoll, L. J., Johnson, D. R., Bryant, M. L., & Gordon, J. I. (1995). Functional significance of
 myristoyl moiety in N-myristoyl proteins. *Methods in Enzymology*, 250, 405-435.
- Kosciuk, T., Price, I. R., Zhang, X., Zhu, C., Johnson, K. N., Zhang, S., et al. (2020). NMT1
 and NMT2 are lysine myristoyltransferases regulating the ARF6 GTPase cycle. *Nature Communications*, 11, 1067.
- Liebschner, D., Afonine, P. V., Moriarty, N. W., Poon, B. K., Sobolev, O. V., Terwilliger, T.
 C., et al. (2017). Polder maps: improving OMIT maps by excluding bulk solvent. *Acta Crystallographica Section D*, *73*, 148-157.

37

- Lodge, J. K., Jackson-Machelski, E., Devadas, B., Zupec, M. E., Getman, D. P., Kishore, N.,
 et al. (1997). N-myristoylation of Arf proteins in Candida albicans: an in vivo assay for
 evaluating antifungal inhibitors of myristoyl-CoA: protein N-myristoyltransferase. *Microbiology, 143*, 357-366.
- Madeo, G., Savojardo, C., Martelli, P. L., & Casadio, R. (2022). SVMyr: a Web server
 detecting co- and post-translational myristoylation in proteins. *Journal of Molecular Biology*, 434, 167605.
- Martin, D. D., Beauchamp, E., & Berthiaume, L. G. (2011). Post-translational myristoylation:
 Fat matters in cellular life and death. *Biochimie*, *93*, 18-31.
- 903 McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read,
- R. J. (2007). Phaser crystallographic software. *Journal of Applied Crystallography*, 40,
 658-674.
- Meinnel, T. (2022). Comment on "Binding affinity determines substrate specificity and enables
 discovery of substrates for N-Myristoyltransferases". *ACS Catalysis, 12*, 8195-8201.
- Meinnel, T., Dian, C., & Giglione, C. (2020). Myristoylation, an ancient protein modification
 mirroring eukaryogenesis and evolution. *Trends in Biochemical Sciences*, 45, 619-632.
- 910 Mousnier, A., Bell, A. S., Swieboda, D. P., Morales-Sanfrutos, J., Perez-Dorado, I., Brannigan,
- J. A., et al. (2018). Fragment-derived inhibitors of human N-myristoyltransferase block
 capsid assembly and replication of the common cold virus. *Nature Chemistry*, 10, 599606.
- Murshudov, G. N., Skubak, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A.,
 et al. (2011). REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallographica Section D*, 67, 355-367.
- Nautiyal, K., & Kuroda, Y. (2018). A SEP tag enhances the expression, solubility and yield of
 recombinant TEV protease without altering its activity. *New Biotechnology*, *42*, 77-84.

- 919 Neopane, K., Kozlov, N., Negoita, F., Murray-Segal, L., Brink, R., Hoque, A., et al. (2022).
 920 Blocking AMPK β1 myristoylation enhances AMPK activity and protects mice from
 921 high-fat diet-induced obesity and hepatic steatosis. *Cell Reports, 41*, 111862.
- Padovani, D., Zeghouf, M., Traverso, J. A., Giglione, C., & Cherfils, J. (2013). High yield
 production of myristoylated Arf6 small GTPase by recombinant N-myristoyl
 transferase. *Small GTPases*, 4, 3-8.
- Pierre, M., Traverso, J. A., Boisson, B., Domenichini, S., Bouchez, D., Giglione, C., et al.
 (2007). N-Myristoylation regulates the SnRK1 pathway in Arabidopsis. *The Plant Cell*, *19*, 2804-2821.
- Rivière, F., Dian, C., Dutheil, R. F., Monassa, P., Giglione, C., & Meinnel, T. (2022). Structural
 and large-scale analysis unveil the intertwined paths promoting NMT-catalyzed lysine
 and glycine myristoylation. *Journal of Molecular Biology*, 434, 167843.
- Rivière, F., Monassa, P., Giglione, C., & Meinnel, T. (2023). Kinetic and catalytic features of
 N-myristoyltransferases. *Methods in Enzymology*, *686*, Chapter 26.
- Rocque, W. J., McWherter, C. A., Wood, D. C., & Gordon, J. I. (1993). A comparative analysis
 of the kinetic mechanism and peptide substrate specificity of human and
 Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. *Journal of Biological Chemistry*, 268, 9964-9971.
- Rudnick, D. A., Duronio, R. J., & Gordon, J. I. (1992). Methods for studying myristoylcoenzyme A: protein N-myristoyltransferase. In N. M. Hooper & A. J. Turner (Eds.),
- 939 *Lipid modification by proteins. A practical approach* (pp. 37-61). Oxford: IRL Press.
- 940 Rudnick, D. A., McWherter, C. A., Gokel, G. W., & Gordon, J. I. (1993).
- 941 MyristoylCoA:protein N-myristoyltransferase. *Advances in Enzymology and Related*942 *Areas of Molecular Biology*, 67, 375-430.

- 943 Rudnick, D. A., McWherter, C. A., Rocque, W. J., Lennon, P. J., Getman, D. P., & Gordon, J.
- I. (1991). Kinetic and structural evidence for a sequential ordered Bi Bi mechanism of
 catalysis by Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. *Journal of Biological Chemistry*, 266, 9732-9739.
- Salah Ud-Din, A. I., Tikhomirova, A., & Roujeinikova, A. (2016). Structure and functional
 diversity of GCN5-related N-acetyltransferases (GNAT). *International Journal of Molecular Sciences*, 17, E1018.
- Schuttelkopf, A. W., & van Aalten, D. M. (2004). PRODRG: a tool for high-throughput
 crystallography of protein-ligand complexes. *Acta Crystallographica Section F, 60*,
 1355-1363.
- Shimada, T., Suzuki, M., & Katakura, S. I. (2015). Structure of N-myristoyltransferase from
 Aspergillus fumigatus. *Acta Crystallographica Section D*, *71*, 754-761.
- Suzuki, T., Ito, M., Ezure, T., Shikata, M., Ando, E., Utsumi, T., et al. (2006). N-Terminal
 protein modifications in an insect cell-free protein synthesis system and their
 identification by mass spectrometry. *Proteomics*, *6*, 4486-4495.
- 958 Suzuki, T., Moriya, K., Nagatoshi, K., Ota, Y., Ezure, T., Ando, E., et al. (2010). Strategy for
- 959 comprehensive identification of human N-myristoylated proteins using an insect cell960 free protein synthesis system. *Proteomics, 10*, 1780-1793.
- 961 Thinon, E., Serwa, R. A., Broncel, M., Brannigan, J. A., Brassat, U., Wright, M. H., et al.
- 962 (2014). Global profiling of co- and post-translationally N-myristoylated proteomes in
 963 human cells. *Nature Communications*, *5*, 4919.
- 964 Tickle, I. J., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., Vonrhein, C., et al. (2018).
 965 STARANISO (http://staraniso.globalphasing.org/cgi-bin/staraniso.cgi).
- Towler, D. A., Gordon, J. I., Adams, S. P., & Glaser, L. (1988). The biology and enzymology
 of eukaryotic protein acylation. *Annual Review of Biochemistry*, *57*, 69-99.

968	Traverso, J. A., Giglione, C., & Meinnel, T. (2013a). High-throughput profiling of N-
969	myristoylation substrate specificity across species including pathogens. Proteomics, 13,
970	25-36.

- 971 Traverso, J. A., Micalella, C., Martinez, A., Brown, S. C., Satiat-Jeunemaitre, B., Meinnel, T.,
 972 et al. (2013b). Roles of N-Terminal fatty acid acylations in membrane compartment
 973 partitioning: Arabidopsis h-type thioredoxins as a case study. *The Plant Cell, 25*, 1056974 1077.
- 975 Utsumi, T., Nakano, K., Funakoshi, T., Kayano, Y., Nakao, S., Sakurai, N., et al. (2004).
 976 Vertical-scanning mutagenesis of amino acids in a model N-myristoylation motif
 977 reveals the major amino-terminal sequence requirements for protein N-myristoylation.
 978 *Eur J Biochem, 271*, 863-874.
- Vagin, A., & Teplyakov, A. (1997). MOLREP: an automated program for molecular
 replacement. *Journal of Applied Crystallography*, *30*, 1022-1225.
- Wu, J., Tao, Y., Zhang, M., Howard, M. H., Gutteridge, S., & Ding, J. (2007). Crystal structures
 of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and
 inhibitors reveal the functional roles of the N-terminal region. *Journal of Biological Chemistry*, 282, 22185-22194.
- Xu, G., Stupak, J., Yang, L., Hu, L., Guo, B., & Li, J. (2018). Deconvolution in mass
 spectrometry based proteomics. *Rapid Communications in Mass Spectrometry*, 32,
 763-774.
- Yamauchi, S., Fusada, N., Hayashi, H., Utsumi, T., Uozumi, N., Endo, Y., et al. (2010). The
 consensus motif for N-myristoylation of plant proteins in a wheat germ cell-free
 translation system. *FEBS Journal*, 277, 3596-3607.
- 991
- 992

993 Figure Legends

994

Fig. 1. Reactions catalyzed by the main enzymes useful for NMT studies. (A) NMT. (B) ACS,
X is any acyl chain and may possibly end with an azide or an alkyne reactive group. (C) IpaJ.


998 Fig. 2. Electrophoresis analysis of the myristoylation state of a protein target. ARF6-His-tag 999 reactivity with myristate derivatives was probed by denaturing electrophoresis and revealed 1000 using different approaches. (A) 12% SDS-PAGE analysis of ARF6 after Coomassie blue 1001 staining; Lane 1, molecular weight marker; Lane 2, unmodified ARF6; Lane 3 myristoylated 1002 ARF6. Panels B &C. 15% SDS-PAGE ARF6 analysis after labeling with Myr-Alk or myristate 1003 or mixed with plant cell extracts (lanes 3-7) or not (lane 1). The PEG3-azide-TAMRA probe 1004 was reacted at increasing concentrations of 1, 10, 25, 50 and 100 µM (lanes 3-7). Lane 8 1005 corresponds to ARF6 labeled with the unclickable physiological myristate. Lane 2 is the 1006 molecular marker. (B) Coomassie blue staining (C) TAMRA fluorescence imaging of the same 1007 gel after azide-TAMRA click reaction. The two arrows indicate the unmodified (top) and 1008 modified (bottom) versions of ARF6. Only the modified, faster migrating version reacts with 1009 the TAMRA click probe. (D) Coomassie blue (left panel) and TAMRA fluorescence after 1010 azide-TAMRA-biotin click reaction (right panel) signals of protein samples from HEK293 1011 protein lysates (40 µg/lane) analyzed by SDS-PAGE. Cells were fed with Myr-Alk or not and 1012 ARF6-Flag was overexpressed or not, as indicated. (E) HEK293 protein lysates overproducing 1013 samples ARF6-Flag (INP, input) were immunoprecipitated (IP) and analyzed by SDS-PAGE 1014 and revealed by blue staining (left panel) or by immunoblotting with anti-Flag antibody (right 1015 panel).

1016

1017 Fig. 3. MALDI MS IpaJ pipeline applied to myristoylation of full-length protein ARF6. The 1018 monocharged (z=1) and doubly-charged (z=2) masses are visible on the m/z MALDI MS 1019 spectrum. The spectra displayed in the figure were obtained with HsNMT2. Similar data were 1020 obtained with HsNMT1. Masses are deduced from the more resolute doubly charged masses. 1021 (A) T0, ARF6 protein alone. (B) T1, myristoylated ARF6 (Myr-ARF6) on its N-terminal Gly. (C) T3, ARF6 devoid of N-terminal Gly as a result of IpaJ action (AG-ARF6) and 1022 1023 remyristoylation of the Lys2 side chain by NMT (Δ G-Myr(K)-ARF6). (D) Recapitulation of 1024 the complete IpaJ pipeline with expected masses at each step and comparison between 1025 theoretical and measured masses.


1026

1027 Fig. 4. Main structural components of NMTs. (A) AlphaFold-predicted 3D structures of 1028 HsNMT1 and HsNMT2 (UniProt entries P30419 and O60551, AlphaFold IDs AF-P30419-F1 1029 and AF-O60551-F1). Overlap of the two structures each displayed in green and pink, 1030 respectively. The additional N-terminal helix (17 residues long) is displayed on top of the 1031 panel. The structures correspond to residues 85-496 and 88-498, respectively. The disordered 1032 N-terminus is not displayed. Both Myristoyl-CoA and peptide ligands at their binding sites are 1033 figured in orange and yellow, respectively. (B) Detailed "fofc omit" sigmaA-weighted electron 1034 density maps (mFobs – DFcalc, PHIcalc) are shown in grey for each of the structures with 1035 peptide ligand *ac*-K undergoing Lys-myristoylation., Myr, MyrCoA, and CoA carbon atoms 1036 are in orange when unlinked to the peptide moiety and in green when covalently bound to the 1037 peptide. (C) Overlap of GK (HPCA) with acK (A subunit).



ò





0=

 \cap

НŌ

Fig. 1

